BEIJING SUCCEEDER TECHNOLOGY INC.

Those taking blood thinners should be cautious when eating bananas. Beijing Succeeder assists with thrombosis and hemostasis diagnosis.

Bananas are often considered a healthy fruit due to their rich nutritional content, including vitamins and minerals. However, for those taking blood thinners, bananas may pose hidden health risks.

Blood thinners, such as the common warfarin, are primarily used to prevent and treat thrombotic disorders. Patients with conditions such as heart valve replacement surgery, atrial fibrillation, and lower limb venous thrombosis often require long-term use. Their mechanism of action is to inhibit the activation of vitamin K-dependent coagulation factors, thereby reducing the risk of blood clotting and ensuring smooth blood circulation. Bananas are a fruit rich in vitamin K, with approximately 10 micrograms per 100 grams. Vitamin K acts as an "activator" of the coagulation system, promoting the activation of coagulation factors and accelerating blood clotting. When patients taking blood thinners consume large amounts of bananas, their vitamin K levels increase significantly. This can counteract the effects of the medication, reducing the effectiveness of the blood thinner and dramatically increasing the risk of blood clots. A hypertensive patient who had been taking warfarin for three years experienced uncontrolled coagulation markers after consuming a banana smoothie with breakfast for a week, ultimately leading to hospitalization for a stroke. This case serves as a wake-up call for patients taking blood thinners.

However, this does not mean that people taking blood thinners should completely avoid bananas. According to the "Dietary Guidelines for Chinese Residents (2022), adults should consume 200-350 grams of fruit daily, roughly equivalent to one to two bananas. Moderate consumption generally does not significantly affect the effectiveness of blood thinners. However, the key is to maintain a balanced and stable diet and avoid large fluctuations in vitamin K intake over short periods of time.

Beijing Succeeder Technology Inc. (stock code: 688338) is a leader in the field of in vitro diagnostics for thrombosis and hemostasis. Founded in 2003, the company has for many years focused on the research, development, production, and sales of in vitro diagnostic instruments and reagents for thrombosis and hemostasis. Beijing Succeeder provides medical institutions with automated testing instruments, including coagulation, hemorheology, hematocrit, and platelet aggregation, as well as supporting reagents and consumables. Its products are widely used in the prevention, screening, diagnosis, and monitoring of thrombotic and hemorrhagic diseases, including stroke, coronary artery disease, and venous thromboembolism.

In 2023, Beijing Succeeder's fully automated coagulation analyzer achieved IVDR CE registration, further demonstrating its technological strength and product quality in the in vitro diagnostic field. Data released on August 17 of the same year showed that the company achieved operating revenue of 141 million yuan in the first half of the year, a year-on-year increase of 33.19%, and net profit attributable to shareholders of 60.222 million yuan, a year-on-year increase of 26.91%. Furthermore, Beijing Succeeder has received numerous honors, including being selected for the 2012 National Torch Program Key High-Tech Enterprise List published by the Torch Center of the Ministry of Science and Technology, and ranking 29th in the 2022 China In Vitro Diagnostic Industry Listed Company Net Profit Ranking.

Beijing Succeeder, with its professional products and technologies, provides strong support for clinicians to accurately assess patients' coagulation status, playing a vital role in safeguarding patient health. For patients taking blood thinners, regular monitoring with advanced testing technologies and products, while paying attention to dietary and medication interactions, can better ensure treatment effectiveness and overall health.